The GLP-1 Telehealth Landscape in 2026: What's Changing

The GLP-1 market moved fast. Too fast for most operators.

In 2023, telehealth companies were printing money on semaglutide. By mid-2024, the FDA shortage status became contested territory. By 2025, compounders were getting warning letters. In 2026, the brands that survive are the ones with infrastructure flexible enough to adapt — not just to the pharmacy landscape, but to the clinical one.

Here’s what’s actually happening and what it means for new brands entering the space.

Compounding Is Not Gone — But It’s Harder

The FDA’s position on compounding is nuanced in ways that matter operationally. Section 503A pharmacies (patient-specific) operate under different rules than 503B outsourcing facilities (larger-batch production for office use).

Most telehealth brands were routing through 503A compounds. As FDA scrutiny increased, the brands that had 503B relationships — or access to commercial semaglutide — maintained continuity. Those without scrambled.

The lesson: pharmacy flexibility isn’t a luxury, it’s risk management.

Differentiation Is Moving Upstream

When everyone has access to the same molecule, differentiation moves to the clinical layer. Programs that win in 2026 have:

• Metabolic panels + follow-up — not just a prescription, but a care loop
• Personalized dosing protocols — titration schedules based on outcomes, not templates
• Adjunct support — coaching, nutrition, behavioral health woven into the program

This is good for patients. It’s also a real operational lift for brands that don’t have the clinical infrastructure to support it.

What This Means for New Entrants

If you’re building a GLP-1 brand today, the path forward isn’t “find a compounder.” It’s:

1. Build on infrastructure that can route across multiple pharmacy partners
2. Design your clinical program to support follow-up, not just onboarding
3. Have a compliance team (or partner) who watches FDA guidance weekly

The opportunity is still enormous. The US obesity market is massive and undertreated. But the easy arbitrage days are over. The brands that build with a real foundation — and real clinical intent — are the ones that will still be running in three years.

Remedora’s pharmacy layer supports both 503A and 503B routing, with commercial fallback options. See how it works →